Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers

被引：0
|
作者：
Burnier, M [1 ]
Buclin, T [1 ]
Biollaz, J [1 ]
Nussberger, J [1 ]
Waeber, B [1 ]
Brunner, HR [1 ]
机构：
[1] CHU VAUDOIS,DIV HYPERTENS & CLIN PHARMACOL,CH-1010 LAUSANNE,SWITZERLAND
来源：
KIDNEY INTERNATIONAL | 1996年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S24 / S29
页数：6
相关论文
共 50 条
  • [41] ENALAPRIL CLINICAL PHARMACOKINETICS AND PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS - AN OVERVIEW
    MACFADYEN, RJ
    MEREDITH, PA
    ELLIOTT, HL
    CLINICAL PHARMACOKINETICS, 1993, 25 (04) : 274 - 282
  • [42] PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS FOR TOPICAL STEROIDS IN VASOCONSTRICTOR TEST
    BARRY, BW
    BRACE, AR
    NORRIS, AC
    WOODFORD, R
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1975, 27 : P75 - P75
  • [43] Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of Monoclonal Antibodies in Children
    Edlund, Helena
    Melin, Johanna
    Parra-Guillen, Zinnia P.
    Kloft, Charlotte
    CLINICAL PHARMACOKINETICS, 2015, 54 (01) : 35 - 80
  • [44] USE OF PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS IN THE DEVELOPMENT OF NEW ANTHRACYCLINES
    ROBERT, J
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (02) : 99 - 102
  • [45] Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone
    Kaiko, RF
    Benziger, DP
    Fitzmartin, RD
    Burke, BE
    Reder, RF
    Goldenheim, PD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) : 52 - 61
  • [46] PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS IN PHASE-I PHASE-II OF DRUG DEVELOPMENT
    VANPEER, A
    SNOECK, E
    HUANG, ML
    HEYKANTS, J
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (01) : 49 - 59
  • [47] Consider pharmacodynamic differences when prescribing angiotensin II receptor antagonists
    不详
    SOUTH AFRICAN MEDICAL JOURNAL, 1998, 88 : C183 - C183
  • [48] The new angiotensin II receptor antagonist, irbesartan - Pharmacokinetic and pharmacodynamic considerations
    Brunner, HR
    AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) : 311S - 317S
  • [49] Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers
    Smolders, Elise J.
    Colbers, Angela
    de Kanter, Clara T. M. M.
    Velthoven-Graafland, Kirsten
    Wolberink, Leonie T.
    Kolmer, Noor van Ewijk-Beneken
    Drenth, Joost P. H.
    Aarnoutse, Rob E.
    Tack, Cees J.
    Burger, David M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (10) : 2225 - 2234
  • [50] Pharmacokinetic-Pharmacodynamic Modelling of Opioids in Healthy Human Volunteers. A MiniReview
    Lorenzini, Kuntheavy Ing
    Daali, Youssef
    Dayer, Pierre
    Desmeules, Jules
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 110 (03) : 219 - 226
12345